Novo to Build Prefilled Insulin Pen Facility in Iran
Novo Nordisk will build a local manufacturing plant for FlexPen prefilled insulin delivery devices in Iran.
Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran have signed a Memorandum of Understanding committing Novo Nordisk to build a local manufacturing plant for FlexPen prefilled insulin delivery devices in Iran, the company announced in a Sept. 22, 2015 press release.
The project is expected to last five years and represents a Novo Nordisk investment of approximately 70 million Euros (US$78 million). With construction of the GMP facility, Novo Nordisk will create 160 jobs; Novo Nordisk already employs approximately 130 people in Iran.
"We are happy to commit to this manufacturing facility in Iran. It signals our long-term commitment to Iran, a country where close to five million people have diabetes according to the International Diabetes Federation. This investment will ensure availability of our modern insulins and will bring us a step closer to the people who rely on our products," said Ole Moelskov Bech, corporate vice-president of Novo Nordisk business area Near East, in the release.
Source: Novo Nordisk
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
